Clifford Molin, MD
Sleep Medicine · Las Vegas, NVNPI 1194707547
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,704 of the $4,189 with a category attached, or 88.4%. 27 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 27.0% of the total. 2025 is the largest year on record at $1,473, 2.2 times the $665 reported in 2019.
Across 148 payments — averaging $28.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$1K
- Jazz Pharmaceuticals Inc.$509
- Pfizer$370
- Novo Nordisk$332
- Abbott$329
- Amgen$246
- plus $1K from 21 others
Across 27 payments — averaging $553.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$11K
- Regeneron$3K
- Shionogi Inc$600
What the payments were for
- Travel & lodging$2947%
- Food & beverage$3,70488%
- Education$1905%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 15 | $1,133 |
| Jazz Pharmaceuticals Inc. | 14 | $509 |
| Pfizer | 19 | $370 |
| Novo Nordisk | 15 | $332 |
| Abbott | 10 | $329 |
| Amgen | 11 | $246 |
| AbbVie | 13 | $246 |
| Astellas Pharma US Inc | 8 | $161 |
| E.r. Squibb & Sons, L.L.C. | 1 | $104 |
| Lilly USA, LLC | 6 | $103 |
| Boehringer Ingelheim | 5 | $93 |
| AstraZeneca | 6 | $90 |
| Hologic Sales And Service, LLC | 4 | $74 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Sanofi Pasteur Inc. | 2 | $50 |
| GSK | 2 | $41 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $33 |
| Johnson & Johnson(2 entities) | 2 | $29 |
| Cvrx, Inc. | 1 | $27 |
| Baxter Healthcare | 1 | $25 |
| Itamar Medical Inc | 1 | $19 |
| Exact Sciences | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $14 |
| Merck | 1 | $13 |
| Nalpropion Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$506
- Inspire Upper Airway Stimulation System$404
- FREESTYLE LIBRE 3$106
- ELIQUIS$104
- Ozempic$102
How this compares
Too few sleep medicine providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $61,599 |
| EliquisApixaban | 36 | $41,223 |
| JardianceEmpagliflozin | 16 | $27,492 |
| FarxigaDapagliflozin Propanediol | 16 | $23,773 |
| JanuviaSitagliptin Phosphate | 15 | $21,795 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $16,797 |
| TrulicityDulaglutide | 11 | $14,487 |
| EntrestoSacubitril/Valsartan | 12 | $8,736 |
| MyrbetriqMirabegron | 13 | $8,300 |
| Atorvastatin Calcium | 615 | $4,534 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $4,097 |
| Duloxetine Hcl | 72 | $1,775 |
| Amlodipine Besylate | 319 | $1,764 |
| Ezetimibe | 73 | $1,661 |
| Levothyroxine Sodium | 186 | $1,630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $332 | $61,59953 claims |
| PfizerEliquis | $370 | $41,22336 claims |
| Boehringer IngelheimJardiance | $93 | $27,49216 claims |
| AstraZenecaFarxiga | $90 | $23,77316 claims |
| MerckJanuvia | $13 | $21,79515 claims |
| GSKTrelegy Ellipta | $41 | $16,79724 claims |
| Lilly USA, LLCTrulicity | $103 | $14,48711 claims |
| Astellas Pharma US IncMyrbetriq | $161 | $8,30013 claims |
| AbbVieSynthroid | $246 | $1,52235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few sleep medicine providers in Nevadaon file to place this against a meaningful peer group, so we don't.
Other sleep medicine in Las Vegas
- Tara RachakondaLas Vegas$6K
- Mohamed ShamiyaLas Vegas$960
- Hala SammanLas Vegas$388
- Robert ReynaLas Vegas$70
- Umar NasirReno$6K
- Brandon FloresReno$5K
- Kimberly YeagerReno$4K
- Francis Paul BattungReno$2K
- Alexander BlatyNorth Las Vegas$2K
- William TorchReno$297
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.